首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   6965篇
  免费   506篇
  国内免费   21篇
耳鼻咽喉   123篇
儿科学   187篇
妇产科学   185篇
基础医学   906篇
口腔科学   362篇
临床医学   530篇
内科学   1717篇
皮肤病学   162篇
神经病学   489篇
特种医学   312篇
外科学   844篇
综合类   30篇
一般理论   3篇
预防医学   583篇
眼科学   100篇
药学   517篇
中国医学   41篇
肿瘤学   401篇
  2023年   41篇
  2022年   44篇
  2021年   202篇
  2020年   133篇
  2019年   216篇
  2018年   268篇
  2017年   169篇
  2016年   211篇
  2015年   244篇
  2014年   302篇
  2013年   342篇
  2012年   505篇
  2011年   504篇
  2010年   278篇
  2009年   253篇
  2008年   383篇
  2007年   375篇
  2006年   310篇
  2005年   287篇
  2004年   266篇
  2003年   252篇
  2002年   216篇
  2001年   189篇
  2000年   168篇
  1999年   174篇
  1998年   65篇
  1997年   58篇
  1996年   38篇
  1995年   38篇
  1994年   31篇
  1993年   27篇
  1992年   78篇
  1991年   82篇
  1990年   81篇
  1989年   40篇
  1988年   38篇
  1987年   58篇
  1986年   46篇
  1985年   57篇
  1984年   40篇
  1983年   33篇
  1980年   19篇
  1979年   38篇
  1978年   20篇
  1975年   24篇
  1974年   27篇
  1973年   26篇
  1972年   19篇
  1969年   23篇
  1968年   19篇
排序方式: 共有7492条查询结果,搜索用时 31 毫秒
1.
Cheryl L. Rock PhD  RD  Cynthia A. Thomson PhD  RD  Kristen R. Sullivan MS  MPH  Carol L. Howe MD  MLS  Lawrence H. Kushi ScD  Bette J. Caan DrPH  Marian L. Neuhouser PhD  RD  Elisa V. Bandera MD  PhD  Ying Wang PhD  Kimberly Robien PhD  RD  Karen M. Basen-Engquist PhD  MPH  Justin C. Brown PhD  Kerry S. Courneya PhD  Tracy E. Crane PhD  RDN  David O. Garcia PhD  FACSM  Barbara L. Grant MS  RDN  CSO  FAND  Kathryn K. Hamilton MA  RDN  CSO  CDN  FAND  Sheri J. Hartman PhD  Stacey A. Kenfield ScD  Maria Elena Martinez PhD  Jeffrey A. Meyerhardt MD  MPH  Larissa Nekhlyudov MD  MPH  Linda Overholser MD  Alpa V. Patel PhD  Bernardine M. Pinto PhD  Mary E. Platek PhD  RD  CDN  Erika Rees-Punia PhD  MPH  Colleen K. Spees PhD  MEd  RD  LD  FAND  Susan M. Gapstur PhD  Marjorie L. McCullough ScD  RD 《CA: a cancer journal for clinicians》2022,72(3):230-262
The overall 5-year relative survival rate for all cancers combined is now 68%, and there are over 16.9 million survivors in the United States. Evidence from laboratory and observational studies suggests that factors such as diet, physical activity, and obesity may affect risk for recurrence and overall survival after a cancer diagnosis. The purpose of this American Cancer Society guideline is to provide evidence-based, cancer-specific recommendations for anthropometric parameters, physical activity, diet, and alcohol intake for reducing recurrence and cancer-specific and overall mortality. The audiences for this guideline are health care providers caring for cancer survivors as well as cancer survivors and their families. The guideline is intended to serve as a resource for informing American Cancer Society programs, health policy, and the media. Sources of evidence that form the basis of this guideline are systematic literature reviews, meta-analyses, pooled analyses of cohort studies, and large randomized clinical trials published since 2012. Recommendations for nutrition and physical activity during cancer treatment, informed by current practice, large cancer care organizations, and reviews of other expert bodies, are also presented. To provide additional context for the guidelines, the authors also include information on the relationship between health-related behaviors and comorbidities, long-term sequelae and patient-reported outcomes, and health disparities, with attention to enabling survivors' ability to adhere to recommendations. Approaches to meet survivors' needs are addressed as well as clinical care coordination and resources for nutrition and physical activity counseling after a cancer diagnosis.  相似文献   
2.
3.
In the work described here, our aim was to determine, in an elderly population, changes in muscle thickness (MT), cross-sectional area (CSA) and echo intensity (EI) of the quadriceps muscles at four time points (0, 5, 10 and 15 min; i.e., T0, T5, T10 and T15, respectively) after changing from a standing to supine position. Twenty-one elderly participants (14 men: 68.1 ± 4.6 y; 8 women: 66.8 ± 4.1 y) were evaluated at four time points. Rectus femoris CSA (RFCSA), MT and EI of the quadriceps femoris (QF) muscles were assessed. EI significantly increased from T0 to T5, T10 and T15 (p < 0.001), whereas no differences were observed between T5 and T15 in the rectus femoris (RFEI), vastus intermedius (VIEI) and quadriceps femoris (QFEI). No differences were observed between any time points in the RFCSA and MT of QF muscles. In summary, these results suggest that periods >5 min are not necessary to obtain consistent MT and EI measurements of quadriceps femoris muscles in the elderly population.  相似文献   
4.
5.
The application of assisted reproductive technologies (ART) has revolutionised the treatment of human infertility, giving hope to the patients previously considered incapable of establishing pregnancy. While semen analysis is performed to access whether a sample has an adequate number of viable, motile and morphologically normal sperm cells able to achieve fertilisation, sperm selection techniques for ART aim to isolate the most competent spermatozoon which is characterised by the highest fertilising potential. Based on the semen analysis results, the correct sperm selection technique must be chosen and applied. In this review, different sperm selection strategies for retrieving spermatozoa with the highest fertilising potential and their impact on ART outcomes are discussed. In addition, advantages and disadvantages of each method and the best suited techniques for each clinical scenario are described.  相似文献   
6.
7.
The mainstays of treatment for colorectal liver metastases (CRLMs) are surgery and chemotherapy. Chemotherapeutic benefits of tumor shrinkage and systemic control of micrometastases are in part counterbalanced by chemotoxicity that can modify the liver parenchyma, jeopardizing the detection of CRLM. This review addresses the clinical decision-making process in the context of radiographic and pathologic responses, the preoperative imaging workup, and the approaches to the liver for CRLM, which disappear after systemic chemotherapy.  相似文献   
8.
Cancer is one of the major public health problems in our society. It is estimated that more than 18 million new cases are diagnosed worldwide every year; 280,000 in Spain. Incidence in following a growing trend. This epidemic could be controlled with research into new treatments and, above all, with adequate prevention. Primary prevention could prevent avoid up to half of all cases. For many others, secondary prevention is essential, as it make diagnosis possible in the stages of the disease when it is easily curable. These guidelines present the scientific evidence regarding secondary prevention in tumors in which its use is well-accepted: breast, cervical, colorectal, prostate, lung, ovarian, melanoma, and gastric cancer.  相似文献   
9.
10.

Background

Pazopanib has been approved for first-line treatment of patients with metastatic renal-cell carcinoma on the basis of clinical trials that enrolled only patients with adequate renal function. Few data are available on the safety and efficacy of pazopanib in patients with renal insufficiency. This study investigated the effect of kidney function on treatment outcomes in such patients.

Patients and Methods

We retrospectively analyzed data of metastatic renal-cell carcinoma patients treated with pazopanib from January 2010 to June 2016 with respect to renal function. Patients with Modification of Diet in Renal Disease ≤ 60 mL/min/1.73 m2 (group A) were compared to patients with Modification of Diet in Renal Disease > 60 mL/min/1.73 m2 (group B) in terms of progression-free survival, toxicities, response rates, and overall survival.

Results

A total of 229 patients were included: 128 in group A and 101 in group B. Median progression-free survival was 14 months (95% confidence interval [CI], 9.4-18.5) and 17 months (95% CI, 11.4-22.8), and overall survival was 30.5 months (95% CI, 8-53) and 41.4 months (95% CI, 21-62) for group A and group B, respectively, with no significant difference (P = .6). No significant difference between the 2 groups was reported in the incidence of adverse events. Dose reductions were more frequent in group A patients (66% vs. 36%; P = .04).

Conclusion

Although the dose of pazopanib was reduced more frequently in patients with renal impairment, kidney function at therapy initiation does not adversely affect the safety and efficacy of pazopanib.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号